Annual CFO
-$160.87 M
-$36.36 M-29.20%
December 31, 2024
Summary
- As of March 13, 2025, KROS annual cash flow from operations is -$160.87 million, with the most recent change of -$36.36 million (-29.20%) on December 31, 2024.
- During the last 3 years, KROS annual CFO has fallen by -$98.72 million (-158.85%).
- KROS annual CFO is now -2384.42% below its all-time high of $7.04 million, reached on December 31, 2018.
Performance
KROS Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$46.01 M
-$15.51 M-50.85%
December 31, 2024
Summary
- As of March 13, 2025, KROS quarterly cash flow from operations is -$46.01 million, with the most recent change of -$15.51 million (-50.85%) on December 31, 2024.
- Over the past year, KROS quarterly CFO has stayed the same.
- KROS quarterly CFO is now -3124.11% below its all-time high of -$1.43 million, reached on March 31, 2022.
Performance
KROS Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$160.87 M
-$20.55 M-14.64%
December 31, 2024
Summary
- As of March 13, 2025, KROS TTM cash flow from operations is -$160.87 million, with the most recent change of -$20.55 million (-14.64%) on December 31, 2024.
- Over the past year, KROS TTM CFO has stayed the same.
- KROS TTM CFO is now -6301.47% below its all-time high of -$2.51 million, reached on March 31, 2019.
Performance
KROS TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
KROS Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -29.2% | 0.0% | 0.0% |
| 3 y3 years | -158.8% | -135.2% | -158.8% |
| 5 y5 years | -905.6% | -736.8% | -905.6% |
KROS Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -158.8% | at low | -3124.1% | at low | -203.1% | at low |
| 5 y | 5-year | -905.6% | at low | -3124.1% | at low | -905.6% | at low |
| alltime | all time | -2384.4% | at low | -3124.1% | at low | -6301.5% | at low |
Keros Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | -$160.87 M(+29.2%) | -$46.01 M(+50.8%) | -$160.87 M(+14.6%) |
| Sep 2024 | - | -$30.50 M(-23.4%) | -$140.32 M(-2.4%) |
| Jun 2024 | - | -$39.80 M(-10.7%) | -$143.80 M(+6.7%) |
| Mar 2024 | - | -$44.56 M(+75.0%) | -$134.83 M(+8.3%) |
| Dec 2023 | -$124.51 M(+77.7%) | -$25.46 M(-25.1%) | -$124.51 M(+3.3%) |
| Sep 2023 | - | -$33.98 M(+10.2%) | -$120.49 M(+8.4%) |
| Jun 2023 | - | -$30.83 M(-9.9%) | -$111.11 M(+8.0%) |
| Mar 2023 | - | -$34.23 M(+59.7%) | -$102.87 M(+46.8%) |
| Dec 2022 | -$70.06 M(+12.7%) | -$21.44 M(-12.8%) | -$70.06 M(+2.8%) |
| Sep 2022 | - | -$24.60 M(+8.9%) | -$68.18 M(+17.5%) |
| Jun 2022 | - | -$22.59 M(+1483.0%) | -$58.02 M(+9.3%) |
| Mar 2022 | - | -$1.43 M(-92.7%) | -$53.07 M(-14.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2021 | -$62.15 M(+68.5%) | -$19.57 M(+35.5%) | -$62.15 M(+22.9%) |
| Sep 2021 | - | -$14.44 M(-18.1%) | -$50.57 M(+7.6%) |
| Jun 2021 | - | -$17.64 M(+67.9%) | -$46.99 M(+19.6%) |
| Mar 2021 | - | -$10.51 M(+31.5%) | -$39.28 M(+6.5%) |
| Dec 2020 | -$36.89 M(+130.6%) | -$7.99 M(-26.4%) | -$36.89 M(+7.2%) |
| Sep 2020 | - | -$10.86 M(+9.4%) | -$34.40 M(+29.8%) |
| Jun 2020 | - | -$9.93 M(+22.3%) | -$26.50 M(+22.7%) |
| Mar 2020 | - | -$8.12 M(+47.7%) | -$21.61 M(+35.0%) |
| Dec 2019 | -$16.00 M(-327.2%) | -$5.50 M(+86.1%) | -$16.00 M(+52.4%) |
| Sep 2019 | - | -$2.96 M(-41.3%) | -$10.50 M(+39.2%) |
| Jun 2019 | - | -$5.03 M(+100.2%) | -$7.54 M(+200.2%) |
| Mar 2019 | - | -$2.51 M | -$2.51 M |
| Dec 2018 | $7.04 M | - | - |
FAQ
- What is Keros Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Keros Therapeutics?
- What is Keros Therapeutics annual CFO year-on-year change?
- What is Keros Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Keros Therapeutics?
- What is Keros Therapeutics quarterly CFO year-on-year change?
- What is Keros Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Keros Therapeutics?
- What is Keros Therapeutics TTM CFO year-on-year change?
What is Keros Therapeutics annual cash flow from operations?
The current annual CFO of KROS is -$160.87 M
What is the all time high annual CFO for Keros Therapeutics?
Keros Therapeutics all-time high annual cash flow from operations is $7.04 M
What is Keros Therapeutics annual CFO year-on-year change?
Over the past year, KROS annual cash flow from operations has changed by -$36.36 M (-29.20%)
What is Keros Therapeutics quarterly cash flow from operations?
The current quarterly CFO of KROS is -$46.01 M
What is the all time high quarterly CFO for Keros Therapeutics?
Keros Therapeutics all-time high quarterly cash flow from operations is -$1.43 M
What is Keros Therapeutics quarterly CFO year-on-year change?
Over the past year, KROS quarterly cash flow from operations has changed by $0.00 (0.00%)
What is Keros Therapeutics TTM cash flow from operations?
The current TTM CFO of KROS is -$160.87 M
What is the all time high TTM CFO for Keros Therapeutics?
Keros Therapeutics all-time high TTM cash flow from operations is -$2.51 M
What is Keros Therapeutics TTM CFO year-on-year change?
Over the past year, KROS TTM cash flow from operations has changed by $0.00 (0.00%)